



Monday / June 1, 2020

13:00 - 16:00		Lung / HNO		Presented by: PD Dr. med. Alessandra Curioni, Prof. Dr. med. Miklos Pless Live experts: Dr. Stefanie Hayoz, Prof. Dr. med. Wolfram Jochum, PD Dr. med. Ulf Petrusch, Prof. Dr. med. Daniel R. Zwahlen	
Abstract no	Entity	First Author	Titel	Link to the video	
9001	SCLC	Rudin	KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).	https://meetinglibrary.asco.org/record/184545/video	
9007	SCLC	Gronberg	Randomized phase II trial comparing the efficacy of standard-dose with high-dose twice-daily thoracic radiotherapy (TRT) in limited disease small-cell lung cancer (LD SCLC).	https://meetinglibrary.asco.org/record/184539/video	
Discussion		Challenging current standards in SCLC			
9501	NSCLC	M Reck	Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC):	https://meetinglibrary.asco.org/record/184808/video	
9503	NSCLC	Rodriguez-Abreu	Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).	https://meetinglibrary.asco.org/record/184799/video	
Discussion		Future perspectives of immunotherapy in NSCLC			
LBA5	NSCLC	Roy S. Herbst	Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIAEGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.	https://meetinglibrary.asco.org/record/184808/video	
9515	NSCLC	Gainor	Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).	https://meetinglibrary.asco.org/record/184804/video	
Discussion		Can we improve targeted therapy for NSCLC?			
9003	Mesothelioma	Forde	PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study.	https://meetinglibrary.asco.org/record/184552/video	
9004	Mesothelioma	Pagano	Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study.	https://meetinglibrary.asco.org/record/184551/video	
Discussion		Good news in mesothelioma?			
6506	HNO	Menon	Low-cost oral metronomic versus intravenous chemotherapy in recurrent, inoperable and metastatic head and neck cancer: Phase III Metro-CIS study.	https://meetinglibrary.asco.org/record/191594/video	
Discussion		Optimizing treatment in HNO cancers			
16:00		Wrap up / Highlights			

Organizer



Founding Sponsor



Roche Pharma (Schweiz) AG
4052 Basel

Co-Sponsors



WE BRING PROGRESS TO CANCER CARE